Navin Fluorine: Jefferies sees 52% EBITDA rise in Q4FY26

What Jefferies is expecting for the March 2026 quarter

Jefferies expects Navin Fluorine International to post strong growth in the March 2026 quarter, projecting revenue growth of 21% and EBITDA growth of 52%. The brokerage linked the outlook to expansion in Project Nectar and strong demand for the R32 refrigerant. These expectations come as investors track whether recent segment trends in high performance products and contract manufacturing can offset weaker conditions in specialty chemicals.

For a company where segment mix and utilisation matter, the March quarter print will be watched for confirmation of operating leverage. Jefferies’ note also puts the spotlight on refrigerant-linked momentum, particularly R32, which has been an important driver in the high performance products (HPP) business.

Project Nectar and R32 demand in focus

The Jefferies preview points to two specific drivers: expansion in Project Nectar and strong demand for R32. While the note does not quantify Project Nectar capacity or capex in the provided details, it signals that the expansion is material enough to influence quarterly growth rates.

R32 demand is also a recurring theme across recent commentary on Navin Fluorine, with other updates referencing strong sales of R32 and better realisations for R22 as contributors to growth in the HPP segment. Investors typically track these variables because they can shift the company’s margin profile and reduce dependence on the more cyclical specialty chemicals segment.

Stock moves: mixed signals across different updates

Navin Fluorine’s share price action in the provided updates shows sharp variation across different points in time. In one update, the stock moved up 1.50% from its previous close of ₹6,388.00, with the last traded price reported at ₹6,483.50.

In another market snapshot dated 06-Aug, the stock was reported at ₹5,051.35, down ₹121.3 or 2.35%. That update also said the stock fell after two consecutive days of gains and underperformed its sector by 2.44% on the day. Despite that near-term decline, the same snapshot mentioned a year-to-date return of 55.58%, while also flagging weaker participation and valuation concerns.

A separate report noted that shares fell over 3% to an intra-day low of ₹4,435 on Monday after the company reported March 2025 quarter (Q4FY25) results, and at 2:10 PM the stock was quoted at ₹4,444, down 3.3% on the NSE.

Q2 FY25 results: profit down, revenue up

Navin Fluorine’s reported Q2 FY25 numbers provide context for the current debate on growth quality and segment mix. The company reported consolidated net profit of ₹58.82 crore in Q2 FY25, down 2.90% from ₹60.58 crore in Q2 FY24. Revenue from operations rose 9.91% year-on-year to ₹518.56 crore from ₹471.79 crore.

Operating EBITDA was ₹107.35 crore, up 9% year-on-year from ₹98.34 crore. The operating EBITDA margin was reported at 20.70% in Q2 FY25 versus 20.84% in Q2 FY24. Profit before tax was ₹76.75 crore, marginally down 0.58% year-on-year.

Segment split: HPP and CMDO grew, specialty chemicals declined

The Q2 FY25 segment split underlined a mixed demand environment. Revenue from specialty chemicals stood at ₹158 crore, down 15% year-on-year. Over the same period, revenue from HPP was ₹293 crore, up 23% year-on-year, and the contract development and manufacturing organisation (CDMO/CMDO) business was ₹68 crore, up 41% year-on-year.

Another update attributed HPP strength to stable HFO operations, strong R32 sales, and higher realisations for R22. In contrast, specialty chemicals sales were described as impacted by global factors including cautious demand and competitive forces. The company also pointed to strong order visibility for the third and fourth quarter of the fiscal and beyond into fiscal 2026, as per the provided text.

Key financial snapshot table

What analysts and brokerages have been saying

Brokerage views in the provided text show caution alongside selective optimism. Axis Securities downgraded the stock from ‘Buy’ to ‘Hold’ while raising the target price to ₹4,440 from ₹4,300. Separately, another note said estimates were fine-tuned to reflect lower growth in the specialty chemicals segment, with PAT estimates lowered by 12% and 8% for FY25 and FY26, and a ‘Hold’ rating maintained with a target price of ₹3,780.

Bloomberg-tracked analyst positioning was also referenced: out of 28 analysts tracking the company, 17 rated it ‘buy’, six suggested ‘hold’, and five recommended ‘sell’. The average 12-month price target was described as implying a potential upside of 14.5%, based on the provided update.

Price points and targets highlighted in the updates

Why this setup matters for investors

The Jefferies forecast of 21% revenue growth and 52% EBITDA growth for the March 2026 quarter raises expectations for operating leverage, especially if Project Nectar expansion is translating into higher throughput. At the same time, the Q2 FY25 data shows that specialty chemicals weakness can still weigh on overall growth consistency, even when HPP and CMDO perform well.

Some of the provided market commentary also points to concerns on valuation relative to peers and questions over long-term growth potential, despite strong financial metrics such as high return on capital employed and significant net profit growth (without specific figures given in the text). Against that backdrop, investors are likely to focus on whether refrigerant-linked strength and project ramp-ups can sustain profitability without margin erosion.

Conclusion: what to watch next

Navin Fluorine’s near-term narrative is being shaped by a combination of broker expectations for Q4FY26, segment-level divergence, and volatile share price reactions around results and market updates. Jefferies’ view puts Project Nectar and R32 demand at the centre of the March 2026 quarter outlook, while recent reported results show steady revenue growth but softer profit and a marginal margin dip.

The next set of quarterly updates will be watched for confirmation of the projected growth trajectory, the pace of specialty chemicals recovery, and whether HPP and CMDO momentum remains strong as fiscal 2026 approaches.